Preparing the case study [adapted from Buchbinder, Cox, & Casciani, 2014]: (a) Read the case study (“Kleiner-Perkins and Genentech…” (Harvard Business School case, no. 9-813-102)) to identify the main point and key players. Highlight the main points and identify themes. Review, asking questions: What is really going on? What are the problems? What is the main issue? How do the problems relate? What are the underlying issues? Describe how or why these issues developed. (b) Research the problem or issue you have identified to help frame the issue and to make connections to secondary issues. Use journal articles, and not website-based sources. (c) Decide how to "solve" or manage the issue. Consider who should be involved; what their responsibilities might be, strengths and weaknesses, and so on. (d) Identify at least two alternative solutions and analyze their strengths and weaknesses, (or describe why or why not they would be effective). (e ) Select the best alternative and explain how you will measure effectiveness.
Writing the case study [adapted from Buchbinder et al., 2014]:
(a) Include a background statement to introduce what you will write about. Summarize the scenario, but do not restate the scenario. Identify key points, the stakeholders, setting and situation.
(b) Discuss the specific issue and secondary issues and how they relate. Support your analysis and explain your reasoning.
(c) Describe the role perspective contributing to your solution, identifying strengths and weaknesses.
(d) Describe alternatives and the pros and cons of these.
(e) End with a conclusion that addresses how to evaluate the effectiveness of the solution or describe how effective measures should be measured. Some case studies may conclude with a discussion of implications from the case.
The Biotech industry is a lucrative industry attracting over $100 billion dollars a year in venture capital and steadily increasing every year (Pisano, 2006). This has not always been the case. In 1976 the biotech company Genentech became the first biotechnology company in history; with investments of over $300 billion dollars, and thirty years under its belt, there have been few biotech companies that have reached its success (Pisano, 2006).
The company was founded by venture capitalist Robert Swanson and biochemist Herbert Boyer; both determined to involve the private sector funding with recombinant DNA research (Hardymon & Nicholas, 2012). This formulation helped Swanson and Boyer move away from issues placed on the industry by governmental agencies. Through much controversy over ethical issues and related to the environment, their venture flourished.
Herbert Boyer and a geneticist by the name of Stanley Cohen formulated recombinant DNA in the early part of 1970 and with the help of Swanson, Boyer founded Genentech to bring gene-engineered medicines to the public (Genentech, 2014). Humulin, which is human insulin, was the first product of the Genentech empire. It was produced in laboratory in 1978, and was a working methodology of recombinant DNA (Hardymon & Nicholas, 2012). It was intended to improve the lives of those who ...
This 819 word solution includes six quality references. It outlines problems and solutions to the Genentech Case Study. This custom solution introduces the key players in the development of recombinant DNA research. It also addresses the concerns related to such research, along with solutions on how these concerns can be allayed.